Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
IPCALAB
Mr. Pranay Premchand Godha · Mumbai, India · 17,210 employees
₹1,774.50
▼-0.81%IPCALAB's specialty pharmaceuticals business continues to ride the growth wave, but high debt levels pose a concern.
Exchange
NSI
Currency
INR
Day range
₹1,760.00 – ₹1,808.00
52-week range
₹1,251.60 – ₹1,944.90
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis70% confidence
IPCALAB's current price of 1774.5 INR appears in the upper third of its 1-year range, hinting at some level of valuation premium relative to its growth prospects.
8.8% below the 1-year high · trend down
Hedge-fund memo
Today
The stock has lost -0.81% today after a day of trading in the lower end of its 1760-1808 range, indicating some selling pressure.
This week
The 52-week high of 1944.9 is the current resistance; the low of 1251.6 is the support.
This month
Month-on-month performance could be a key area of focus for investors as it has shown a positive trend overall.
Bull thesis
Bear thesis
Hidden risks
News & sentiment
Bullish
1 headlines · 1 outlets · 7d
TradingView·2d ago·large multi-year AI deal
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 4 of 4 recent quarters (EPS actual vs. consensus).
13.31 vs 10.454
27.32% surprise
12.09 vs 11.61333
4.10% surprise
12.35 vs 10.72
15.21% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| IPCALAB | 450.20B | 39.52 | 13.22% | 18.48% | 6.30% |
| ALKEM | 678.23B | 29.43 | 17.56% | 11.42% | 14.60% |
| TORNTPHARM | 1.86T | 76.61 |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 499sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
High debt levels
Mitigation: Focus on deleveraging and maintaining strong profitability through new product launches and R&D initiatives.
Regulatory uncertainty
Mitigation: Maintain a strong track record of compliance and stay up to date with regulatory requirements.
Market competition
Mitigation: Stay competitive through innovation and continuous product development.
Business intelligence
Competitive moat
IPCALAB's strong brand recognition, long history of compliance, and robust research and development efforts give it a competitive moat.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Launch of new products and expansion of the product portfolio.
Thesis builder
Bull case
Riding the wave of specialty pharmaceutical growth and leveraging its strong product pipeline for a potential multi-bagger.
Base case
Solid business fundamentals, with a stable product portfolio driving steady growth.
Bear case
High debt and reliance on key products could lead to significant volatility and erosion in the core business values.
Time horizon
12-18 months to potentially break the Rs. 2000 barrier.
Est. CAGR
approx. 15-20% over the 12-18 month horizon.
Entry (qual.)
On a potential dip in the range or when valuations are more reasonable, re-enter with a medium to long-term perspective.
Exit (qual.)
Sell on the 52-week high resistance level around Rs. 1944.9 or when valuations appear overdone.
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how IPCALAB fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain IPCALAB for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden opportunities
Watch next
Monitor the stock for potential dips in the range and re-enter with a medium to long-term perspective.
Annual income statement, oldest → newest. Live via Yahoo.
9.19 vs 9.16
0.33% surprise
| 16.99% |
| 20.20% |
| 41.80% |
| AJANTPHARM | 424.34B | 40.17 | 25.39% | 23.19% | 21.50% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹1,760.00
Resistance (day/52w high)
₹1,808.00
Volume
1,55,849
Trend
down
RSI (14)
51
MACD
bearish
MA cross
golden
50-day MA
₹1,675.90
200-day MA
₹1,514.96
vs 200-DMA
17.1%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.
Overall conviction 70%